STOCK TITAN
  1. Home
  2. News
  3. AKTX

Akari Therapeutics Plc - AKTX STOCK NEWS

Welcome to our dedicated news page for Akari Therapeutics Plc (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akari Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akari Therapeutics Plc's position in the market.

News
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
Rhea-AI Summary
Akari Therapeutics announces private placement of equity securities and receipt of UK R&D tax credit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
News
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
Rhea-AI Summary
Akari Therapeutics to host virtual event on October 19, 2023 to discuss potential treatment for HSCT-TMA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
-
News
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Akari Therapeutics regains compliance with minimum bid price requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
none
News
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
Rhea-AI Summary
Akari Therapeutics establishes U.S. headquarters in Boston Seaport area to support expansion and clinical trials
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
clinical trial
-
News
Akari Therapeutics, Plc Announces ADS Ratio Change
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) will change the ratio of its ADSs to ordinary shares from 1:100 to 1:2000 to regain compliance with Nasdaq minimum bid price requirement. Each ADS holder will exchange 20 ADSs for 1 new ADS. No change to underlying ordinary shares. Fractional entitlements will be sold and proceeds distributed to ADS holders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.4%
Tags
none
-
News
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) appoints Beth-Anne Lang as Senior Vice President, Regulatory Affairs. Lang brings over 20 years of experience in regulatory strategy and drug development. She will focus on advancing Phase 3 clinical trials in pediatric and adult HSCT-TMA and the PAS-nomacopan program. Lang's track record includes successful drug approvals in the U.S. and globally, making her expertise valuable for Akari's urgent regulatory filings. Before Akari, Lang led regulatory strategy for rare disease therapeutics at Enzyvant Therapeutics and Horizon Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
management
News
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.16%
Tags
clinical trial
-
News
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
management
-
News
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
Rhea-AI Summary
Akari Therapeutics announces updates in the development programs for nomacopan, a treatment for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). They are on track to begin enrollment in a Phase 3 study for pediatric HSCT-TMA by the end of 2023. They also plan to move forward with a Phase 3 trial for adult HSCT-TMA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
none
News
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock AKTX logo
Akari Therapeutics Plc

Nasdaq:AKTX

AKTX Rankings

N/A Ranked by Market Cap
#4941 Ranked by Stock Gains
N/A Ranked by Dividends

AKTX Stock Data

9.16M
9.56B
17.91%
1.61%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AKTX

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.